MRX-2843 also enhanced inhibition of downstream oncogenic signaling in combination with third-generation EGFR TKIs, including osimertinib, resulting in more robust anti-tumor activity both in vitro and in vivo [69,80]. Here, EGFR is linked to neoplasm.